anonymous
Guest
anonymous
Guest
Rumor is that rheum and neph sales not going to make goal. Any word on the other ARD disease states? Could be a painful quarter. Worse is that the Acthar franchise appears to be unraveling at an accelerating rate. Less in and less out.